Telix Pharmaceuticals has completed Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) for TLX250-CDx (Zircaix), a radiodiagnostic agent for identifying clear cell renal cell carcinoma (ccRCC) in kidney cancer patients.
FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.
PharmaLogic, a contract development and manufacturing organization (CDMO) and provider of radiopharmacy solutions, has announced the launch of its new radiopharmaceutical manufacturing and research facility at the Bronx in New York city, US.
Latus Bio, a biotechnology company specialising in new gene therapy candidates for central nervous system (CNS) disorders, has announced its launch alongside an initial $54m Series A financing.
Scenic Biotech has entered into a new research partnership with Bristol Myers Squibb, aimed at accelerating the development of new drug targets.
Genmab and Pfizer have announced that the US Food and Drug Administration (FDA) granted full approval to TIVDAK’s (tisotumab vedotin-tftv) supplemental Biologics License Application (sBLA) to treat patients with recurrent or metastatic cervical cancer who have experienced disease progression on or after chemotherapy.
Ractigen Therapeutics has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for saRNA therapy RAG-01.
Ferring Pharmaceuticals and SK pharmteco have entered into an agreement to increase commercial manufacturing capacity for Ferring’s ADSTILADRIN (nadofaragene firadenovec-vncg), ensuring a long-term supply of the non-replicating adenoviral vector-based gene therapy.
Telix Pharmaceuticals has received fast track designation from the US Food and Drug Administration (FDA) for its investigational glioma imaging product, TLX101-CDx (Pixclara).
Clinical-stage immuno-oncology company Portage Biotech has announced plans to expand its assessment of strategic alternatives.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.